Last reviewed · How we verify
THR-149 dose level 1
THR-149 dose level 1 is a Small molecule drug developed by Oxurion. It is currently in Phase 2 development.
THR-149 is a small molecule being studied in a Phase 1 clinical trial for the treatment of Diabetic Macular Edema, Diabetic Retinopathy, and Diabetes Mellitus. The trial involves the administration of THR-149 at different dose levels, starting with dose level 1, to evaluate its safety.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | THR-149 dose level 1 |
|---|---|
| Sponsor | Oxurion |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Study to Evaluate THR-149 Treatment for Diabetic Macular Oedema (PHASE2)
- A Study to Evaluate the Safety of THR-149 in Subjects With Diabetic Macular Edema (DME) (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- THR-149 dose level 1 CI brief — competitive landscape report
- THR-149 dose level 1 updates RSS · CI watch RSS
- Oxurion portfolio CI
Frequently asked questions about THR-149 dose level 1
What is THR-149 dose level 1?
Who makes THR-149 dose level 1?
What development phase is THR-149 dose level 1 in?
Related
- Manufacturer: Oxurion — full pipeline
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing